Cybin advances clinical pipeline and leadership team

Cybin, also known as Helus Pharma, is undergoing significant organizational and strategic shifts as it advances its psychedelic-based therapeutic pipeline. The company recently appointed Regina Donohue as Chief People Officer and added Suresh Durgam to its Scientific Advisory Board. These moves follow the recent appointment of Michael Halstead as CEO, a veteran with 25 years of biopharma experience.

On the scientific front, the company is prioritizing its clinical programs, specifically the Phase 3 APPROACH study for HLP003, a deuterated psilocybin intended to treat Major Depressive Disorder. Patient recruitment for this study has reportedly been completed ahead of schedule. The pipeline also includes HLP004, a deuterated DMT preparation for anxiety disorders.

From a financial perspective, Wells Fargo has maintained an ‘Overweight’ rating on the stock with a price target of 16 USD, despite recent sector volatility. While the company faces the typical risks and financing needs associated with biotechnology research, analysts see potential in its specialized mental health treatments.